Potential cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: current evidence and ongoing trialsMOSENZON, Ofri; RAZ, Itamar.European heart journal supplements. 2012, Vol 14, Num B, issn 1520-765X, B22-B29Article

Intensification of Insulin Therapy for Type 2 Diabetic Patients in Primary Care: Basal-Bolus Regimen Versus Premix Insulin Analogs: When and for whom?MOSENZON, Ofri; RAZ, Itamar.Diabetes care. 2013, Vol 36, issn 0149-5992, S212-S218, SUP2Conference Paper

Early Insulinization to Prevent Diabetes ProgressionRAZ, Itamar; MOSENZON, Ofri.Diabetes care. 2013, Vol 36, issn 0149-5992, S190-S197, SUP2Conference Paper

Spontaneous tumor lysis syndrome in solid tumors: Really a rare condition?VAISBAN, Eleonora; BRAESTER, Andrei; MOSENZON, Ofri et al.The American journal of the medical sciences. 2003, Vol 325, Num 1, pp 38-40, issn 0002-9629, 3 p.Article

Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized TrialSCIRICA, Benjamin M; BRAUNWALD, Eugene; POLLACK, Pia S et al.Circulation (New York, N.Y.). 2014, Vol 130, Num 18, pp 1579-1588, issn 0009-7322, 10 p.Article

Incidence of Pancreatitis and Pancreatic Cancer in a Randomized Controlled Multicenter Trial (SAVOR-TIMI 53) of the Dipeptidyl Peptidase-4 Inhibitor SaxagliptinRAZ, Itamar; BHATT, Deepak L; GREENBERGER, Norton et al.Diabetes care. 2014, Vol 37, Num 9, pp 2435-2441, issn 0149-5992, 7 p.Article

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes MellitusSCIRICA, Benjamin M; BHATT, Deepak L; CAVENDER, Matthew A et al.The New England journal of medicine. 2013, Vol 369, Num 14, pp 1317-1326, issn 0028-4793, 10 p.Article